ManninoDM, HomaDM, AkinbamiLJ, FordES, ReddSC. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. Respir Care, 2002; 47(10):1184–1199.
3.
JemalA, WardE, HaoY, ThunM. Trends in the leading causes of death in the United States, 1970-2002. JAMA, 2005; 294(10):1255–1259.
4.
CelliBR, MacNeeW; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-946. Erratum: Eur Respir J, 2006; 27(1):242.
5.
RabeKF, HurdS, AnzuetoA, BarnesPJ, BuistSA, CalverleyP, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD executive summary Am J Respir Crit Care Med, 2007; 176(6):532–555.
6.
National Collaborating Centre for Chronic Conditions. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 2004; 59(Suppl 1):1–232.
7.
Management of COPD Working Group. VA/DoD clinical practice guideline for management of outpatient chronic obstructive pulmonary disease. Version 2.0, 2007, http://www.healthquality.va.gov/copd/copd20.pdf. Accessed March 5, 2010.
8.
HalpinDM, MiravitllesM. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc, 2006; 3(7):619–623.
9.
PeñaVS, MiravitllesM, GabrielR, Jiménez-RuizCA, VillasanteC, MasaJF, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest, 2000; 118(4):981–989.
10.
HalbertRJ, IsonakaS, GeorgeD, IqbalA. Interpreting COPD prevalence estimates: what is the true burden of disease?. Chest, 2003; 123(5):1684–1692.
11.
HalbertRJ, NatoliJL, GanoA, BadamgaravE, BuistAS, ManninoDM. Global burder of COPD: systematic review and meta-analysis. Eur Respir J, 2006; 28(3):523–532.
12.
ThompsonWH, St-HilaireS. Prevalence of chronic obstructive pulmonary disease and tobacco use in veterans at Boise Veterans Affairs Medical Center. Respir Care, 2010; 55(5):555–560.
13.
LeeTA, BartleB, WeissKB. Spirometry use in clinical practice following diagnosis of COPD. Chest, 2006; 129(6):1509–1515.
14.
HanMK, KimMG, MardonR, RennerP, SullivanS, DietteGB, MartinezFJ. Spirometry utilization for COPD: how do we measure up?. Chest, 2007; 132(2):403–409.
15.
FergusonGT, EnrightPL, BuistAS, HigginsMW. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Respir Care, 2000; 45(5):513–530.
16.
KaminskyDA, MarcyTW, BachandM, IrvinCG. Knowledge and use of office spirometry for the detection of COPD by primary care physicians. Respir Care, 2005; 50(12):1639–1648.
17.
SorianoJB, ZielinskiJ, PriceD. Screening for and early detection of chronic obstructive pulmonary disease. Lancet, 2009; 374(9691):721–732.
18.
US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: US Preventive Service Task Force recommendation statement. Ann Intern Med, 2008; 148(7):529–534.
19.
LinK, WatkinsB, JohnsonT, RodriguezJA, BartonMB; US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the US Preventive Services Task Force. Ann Intern Med, 2008; 148:535–543.
20.
ParkesG, GreenhalghT, GriffinM, DentR. Effect of smoking quit rate on telling patients their lung age: the Step2quite randomized controlled trial. BMJ, 2008; 336(7644):598–600.
21.
CalverleyPM, AndersonJA, CelliB, FergusonGT, JenkinsC, JonesPW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007; 356(8)775–789.
22.
CelliBR, ThomasNE, AndersonJA, FergusonGT, JenkinsCR, JonesPW, et al. Effect of pharmacotherapy on rate of decline in lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med, 2008; 178(4):332–338.
23.
TashkinDP, CelliB, SennS, BurkhartD, KestenS, MenjogeS, DecramerM; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med;, 2008; 359(15):1543–1554.
24.
DecramerM, CelliB, KestenS, LystigT, MehraS, TashkinDP; UPLIFT Investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analyais of a randomized controlled trial. Lancet, 2009; 374(9696):1171–1178.
25.
FabbriLM, CalverleyPM, Izquierdo-AlonsoJL, BundschuhDS, BroseM, MartinezJF, RabeKF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomize clinical trials. Lancet, 2009; 374(9691):695–703.
26.
ChapmanKR, TashkinDP, PyeDJ. Gender bias in the diagnosis of COPD. Chest, 2001; 119(6):1691–1695.
27.
ChapmanKR. Chronic obstructive pulmonary disease: are women more susceptible than men?. Clin Chest Med, 2004; 25(2):331–341.
28.
MachadoML, KrishnanJA, BuistAS, BilderbackAL, FazoloGP, SantarosaMG, et al. Sex differences in survival in oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006; 1745)524–529.
